Karen A Vincent

Author:

Karen Goyette Vincent

ISBN #:

0827361025

US Patent:

6632670, Oct 14, 2003

Filed:

Nov 16, 1998

Appl. No.:

09/029705

Inventors:

Samuel C. Wadsworth - Shrewsbury MA
Karen Vincent - Arlington MA
Susan Piraino - Framingham MA

Assignee:

Genzyme Corporation - Cambridge MA

International Classification:

C12N 15864

US Classification:

435455, 4352351, 4353201, 435456, 435457

Abstract:

The present invention is directed to methods for generating high titer, contaminant free, recombinant AAV vectors, methods and genetic constructs for producing recombinant AAV vectors conveniently and in large quantities, methods for the delivery of all essential viral proteins required in trans for high yields of recombinant AAV, recombinant AAV vectors for use in gene therapy, novel packaging cell lines which obviate the need for cotransfection of vector and helper plasmids, helper plasmids and vector plasmid backbone constructs, a reporter assay for determining AAV vector yield. Further provided are recombinant AAV vectors in a pharmaceutically acceptable carrier, methods of delivering a transgene of interest to a cell, compositions and methods for delivering a DNA sequence encoding a desired polypeptide to a cell, and transgenic non-human mammals that express a human chromosome 19 AAV integration locus.

US Patent:

7053062, May 30, 2006

Filed:

Jul 3, 2002

Appl. No.:

10/190394

Inventors:

Richard J. Gregory - Westford MA, US
Karen Vincent - Arlington MA, US

Assignee:

Genzyme Corporation - Cambridge MA

International Classification:

A61K 31/70
C12N 15/00
C12N 15/63
C07H 21/04

US Classification:

514 44, 4353201, 435455, 536 234

Abstract:

The present invention provides recombinant nucleic acid molecules encoding a chimeric transactivator protein including a DNA binding domain of a DNA binding protein and a protein domain capable of transcriptional activation. The present invention also provides recombinant viral and non-viral vectors that are able to infect and/or transfect and sustain expression of a biologically active chimeric transactivator proteins in mammalian cells. Also provided are host cell lines and non-human transgenic animals capable of expressing biologically active chimeric transactivator proteins. In another aspect, compositions and methods for treating or preventing ischemic damage associated with hypoxia-related disorders are provided.

US Patent:

20040105845, Jun 3, 2004

Filed:

Sep 4, 2003

Appl. No.:

10/656474

Inventors:

Samuel Wadsworth - Shrewsbury MA, US
Karen Vincent - Arlington MA, US
Susan Piraino - Framingham MA, US

International Classification:

A61K048/00
C12N015/861

US Classification:

424/093200, 435/456000

Abstract:

The present invention is directed to methods for generating high titer, contaminant free, recombinant AAV vectors, methods and genetic constructs for producing AAV recombinant vectors conveniently and in large quantities, methods for the delivery of all essential viral proteins required in trans for high yields of recombinant AAV, recombinant AAV vectors for use in gene therapy, novel packaging cell lines which obviate the need for cotransfection of vector and helper plasmids, helper plasmids and vector plasmid backbone constructs, a reporter assay for determining AAV vector yield. Further provided are recombinant AAV vectors in a pharmaceutically acceptable carrier, methods of delivering a transgene of interest to a cell, compositions and methods for delivering a DNA sequence encoding a desired polypeptide to a cell, and transgenic non-human mammals that express a human chromosome 19 AAV integration locus.

US Patent:

20060127361, Jun 15, 2006

Filed:

Feb 13, 2006

Appl. No.:

11/352879

Inventors:

Richard Gregory - Westford MA, US
Karen Vincent - Arlington MA, US

Assignee:

Genzyme Corporation - Cambridge MA

International Classification:

A61K 48/00
C07H 21/04

US Classification:

424093200, 514044000, 536023720

Abstract:

The present invention provides recombinant nucleic acid molecules encoding a chimeric transactivator protein including a DNA binding domain of a DNA binding protein and a protein domain capable of transcriptional activation. The present invention also provides recombinant viral and non-viral vectors that are able to infect and/or transfect and sustain expression of a biologically active chimeric transactivator proteins in mammalian cells. Also provided are host cell lines and non-human transgenic animals capable of expressing biologically active chimeric transactivator proteins. In another aspect, compositions and methods for treating or preventing ischemic damage associated with hypoxia-related disorders are provided.

US Patent:

6432927, Aug 13, 2002

Filed:

May 26, 2000

Appl. No.:

09/579897

Inventors:

Richard J. Gregory - Westford MA
Karen Vincent - Arlington MA

Assignee:

Genzyme Corporation - Cambridge MA

International Classification:

A61K 3170

US Classification:

514 44, 4353201, 435325, 435 914, 435455, 536 234, 536 241, 424 932

Abstract:

The present invention provides recombinant nucleic acid molecules encoding a chimeric transactivator protein including a DNA binding domain of a DNA binding protein and a protein domain capable of transcriptional activation. The present invention also provides recombinant viral and non-viral vectors that are able to infect and/or transfect and sustain expression of a biologically active chimeric transactivator proteins in mammalian cells. Also provided are host cell lines and non-human transgenic animals capable of expressing biologically active chimeric transactivator proteins. In another aspect, compositions and methods for treating or preventing ischemic damage associated with hypoxia-related disorders are provided.

US Patent:

20190048362, Feb 14, 2019

Filed:

Apr 7, 2016

Appl. No.:

15/565020

Inventors:

- Cambridge MA, US
David SOUZA - Waltham MA, US
Karen VINCENT - Carlisle MA, US

International Classification:

C12N 15/86
A61P 11/00
A61K 38/17
A61P 21/00

Abstract:

Provided herein are methods for producing an adeno-associated virus (AAV) particle containing an oversized recombinant AAV genome (e.g., greater than 4.7 kb). In some aspects, the invention provides AAV particles and AAV vectors comprising oversized rAAV genomes. Producer cell lines to produce AAV particles comprising oversized genomes are also provided.